Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis

• Verfasst von: Brunnemer, Eva [VerfasserIn]
• Verfasst von: Wälscher, Julia [VerfasserIn]
• Verfasst von: Tenenbaum, Svenja [VerfasserIn]
• Verfasst von: Hausmanns, Julia [VerfasserIn]
• Verfasst von: Schulze, Karen [VerfasserIn]
• Verfasst von: Seiter, Marianne [VerfasserIn]
• Verfasst von: Heußel, Claus Peter [VerfasserIn]
• Verfasst von: Warth, Arne [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Kreuter, Michael [VerfasserIn]
• Titel: Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis
• Verf.angabe: Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J. F. Herth, Michael Kreuter
• E-Jahr: 2018
• Jahr: February 28, 2018
• Umfang: 9 S.
• Teil: volume:95
• Teil: year:2018
• Teil: number:5
• Teil: pages:301-309
• Teil: extent:9
• Fussnoten: Gesehen am 15.10.2019
• Titel Quelle: Enthalten in: Respiration
• Ort Quelle: Basel : Karger, 1944
• Jahr Quelle: 2018
• Band/Heft Quelle: 95(2018), 5, Seite 301-309
• ISSN Quelle: 1423-0356
• DOI: doi:10.1159/000485933
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1679035150

Abstract

Background: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited. Objective: To assess the efficacy and safety of nintedanib in a large cohort of patients treated at a tertiary referral site for interstitial lung diseases. Methods: The records of patients with a confirmed diagnosis of IPF were reviewed. Full medical history, pulmonary function, and adverse events (AEs) were recorded from each clinic visit. Disease progression was defined as a reduction in FVC ≥5% and/or in diffusing capacity of the lung for carbon monoxide ≥15% according to recent publications. Only patients with a treatment duration ≥3 months were included in the efficacy evaluation. Results: A total of 64 patients were treated. Mean ± standard deviation (SD) FVC was 71 ± 21% predicted, and the mean time from diagnosis to initiation of nintedanib treatment was 23.8 months. Nearly half of patients (n = 30, 47%) had received prior pirfenidone treatment. The mean duration of follow-up was 11 months. At 6 months following initiation of nintedanib, 67% of the patients were stable. The mean ± SD change in percent predicted FVC from baseline was 0.2 ± 7.8% at 3 months, –1.3 ± 7.9% at 6 months, and –2.1 ± 9% at 9 months. Diarrhoea was the most common AE experienced by 33% of patients and was generally manageable. Conclusion: The results from this real-world clinical setting support findings from previously conducted clinical trials and show that nintedanib is effective for the management of IPF and is associated with disease stabilisation. Nintedanib is generally well tolerated.